Bioventus Inc. BVS
Set alert
At close · Oct 30
After hours · Oct 30, 4:22 PM ET
- YTD
- +79.10%
- 1 year
- +96.82%
- Open
- 14.84
- Prev close
- 14.87
- Mkt cap
- 910.17M
- Vol
- 666.69K
- Avg vol
- 562.45K
- EPS
- 0.78
- P/E
- 17.08
- Div yield
- 0.00%
More statistics
- Low
- 13.32
- High
- 14.84
- Forward P/E
- 16.16
- Beta
- 0.64
- Short ratio
- 7.53
- Inst. own
- 84.85%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 2, 2026
- 50-d avg
- 13.72
- 200-d avg
- 10.84
- 1y target
- 17.60
1M chart
Signals (10)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Oct 30, 2026 | 2 days ago |
| SMA: Bearish | Oct 30, 2026 | 2 days ago |
| SMA: Bullish | Oct 20, 2026 | 1 week ago |
| SMA: Bearish | Oct 16, 2026 | 2 weeks ago |
| SMA: Bullish | Oct 15, 2026 | 2 weeks ago |
| MACD: Buy Signal | Oct 14, 2026 | 2 weeks ago |
| SMA: Bullish | Oct 12, 2026 | 2 weeks ago |
| MACD: Sell Signal | Oct 2, 2026 | 1 month ago |
| SMA: Bearish | Oct 1, 2026 | 1 month ago |
| SMA: Bearish | Oct 1, 2026 | 1 month ago |
Key statistics
- Market cap
- 1.02B
- Enterprise value
- 1.28B
- Trailing P/E
- 19.06
- Forward P/E
- 16.16
- PEG ratio
- 1.53
- Price / sales
- 1.75
- Price / book
- 4.44
- EPS (TTM)
- 0.78
- Beta
- 0.64
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 9.36%
- Revenue (TTM)
- 581.85M
- Revenue growth
- 3.80%
- Free cash flow
- 67.76M
- Total cash
- 30.39M
- Total debt
- 263.75M
- Return on equity
- 25.68%
- Shares outstanding
- 68.31M
- Short % of float
- 6.78%
- 50-day average
- 13.72
- 200-day average
- 10.84
Analyst view
Consensus: strong buy
- Target (low)
- 15.00
- Target (mean)
- 17.60
- Target (high)
- 19.00
- Strong buy2
- Buy3
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 2, 2026
Expected Nov 2, 2026. Consensus EPS estimate 0.16.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 2, 2026 | Sep 27, 2026 | 0.1496 | — | — | — |
| Aug 5, 2026 | Jun 27, 2026 | 0.2163 | 0.22 | 0.00 | +1.71% |
| May 6, 2026 | Mar 28, 2026 | 0.09 | 0.15 | +0.06 | +66.67% |
| Mar 5, 2026 | Dec 31, 2025 | 0.22 | 0.24 | +0.02 | +9.09% |
| Nov 4, 2025 | Sep 27, 2025 | 0.215 | 0.15 | -0.06 | -30.23% |
| Aug 6, 2025 | Jun 28, 2025 | 0.22 | 0.21 | -0.01 | -4.55% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 17, 2026 | Canaccord Genuity | main | Buy | Buy |
| Aug 17, 2026 | Cantor Fitzgerald | reit | Overweight | Overweight |
| Jun 30, 2026 | Barrington Research | main | Outperform | Outperform |
| Jun 16, 2026 | Canaccord Genuity | main | Buy | Buy |
| May 22, 2026 | Barrington Research | main | Outperform | Outperform |
| Mar 6, 2026 | Barrington Research | main | Outperform | Outperform |
About Bioventus Inc.
Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion. In addition, the company provides neXus, an ultrasonic surgical system; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; BoneScalpel Access, for bone removal with visualization; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical, and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix. The company's restorative therapies include minimally invasive fracture treatments and rehabilitation products. Its products also include Exogen, an ultrasound bone stimulation system. The company sells its products to healthcare institutions, physicians, patients, distributors and dealers. Bioventus Inc. was founded in 2011 and is headquartered in Durham, North Carolina.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- bioventus.com
News
- Bioventus to Report Third Quarter of Fiscal Year 2026 Financial Results on November 2, 2026
- Bioventus Inc (BVS) Stock Up 3.6% but GF Value Says Overvalued -- GF Score: 63/100
- Comparing Kestra Medical Technologies (NASDAQ:KMTS) & Bioventus (NASDAQ:BVS)
- Reviewing Bioventus (NASDAQ:BVS) & RxSight (NASDAQ:RXST)
- Bioventus: Cash Flow Anchors The Bull Case Beyond A Potential Sale
- Are Medical Stocks Lagging Bioventus (BVS) This Year?
- 4 Healthcare Stocks to Safeguard Your Portfolio as Fed Plans Rate Hike
- Canaccord Genuity Maintains Buy on Bioventus, Raises Price Target to $19
- Cantor Fitzgerald Reiterates Overweight on Bioventus, Maintains $15 Price Target
- Deal Dispatch: Bending Spoons Acquires Airtable, Bain Capital Buys Gong Cha Global, Salad and Go Bankruptcy
Your note
Sign in to keep a note on BVS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BARTHOLDSON JOHN A | Director and Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Jun 1, 2026 | 7,051,260 |
| CLAYPOOLE ROBERT E. | Chief Executive Officer | Conversion of Exercise of derivative security | Mar 12, 2026 | 135,944 |
| D'ADAMIO ANTHONY | General Counsel | Conversion of Exercise of derivative security | Apr 9, 2026 | 153,655 |
| HAWKINS WILLIAM A III | Director | Conversion of Exercise of derivative security | Jun 1, 2026 | 297,640 |
| LADONE MARY KAY | Director | Conversion of Exercise of derivative security | Jun 1, 2026 | 111,263 |
| NEELS GUIDO J | Director | Conversion of Exercise of derivative security | Jun 1, 2026 | 117,523 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Essex Woodlands Management Inc. | 19.06% | 13,021,324 | 193.63M | Jun 29, 2026 |
| Juniper Investment Company, LLC | 10.16% | 6,939,357 | 103.19M | Jun 29, 2026 |
| Nantahala Capital Management, LLC | 8.78% | 6,000,279 | 89.22M | Jun 29, 2026 |
| Blackrock Inc. | 5.03% | 3,435,914 | 51.09M | Jun 29, 2026 |
| Royce & Associates LP | 2.68% | 1,833,212 | 27.26M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 2.56% | 1,751,678 | 26.05M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| American Century ETF Trust-Avantis U.S. Small Cap Value ETF | 2.58% | 1,760,427 | 26.18M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.83% | 1,248,896 | 18.57M | Sep 29, 2026 |
| Brown Advisory Funds-Brown Advisory Small-Cap Fundamental Value Fund | 1.81% | 1,239,520 | 18.43M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.70% | 1,163,677 | 17.30M | Jun 29, 2026 |
| ROYCE FUND-Royce Small-Cap Opportunity Fund | 1.26% | 858,738 | 12.77M | Jun 29, 2026 |
| OBERWEIS FUNDS-Oberweis Micro-Cap Fund | 1.00% | 684,514 | 10.18M | Jun 29, 2026 |